Clopidogrel Dosing Scheme in Pediatric Cardiac Patients 0-24 Months Old Using P2Y₁₂ Reaction Unit Monitoring

Area of Science:

• Cardiology
• Pharmacology
• Pediatrics

Background:

• Clopidogrel is increasingly used for postprocedural thromboprophylaxis in pediatric cardiac patients.
• The current recommended static low dose (0.2 mg/kg/day) for patients under 24 months, established by the PICOLO trial, is being questioned.

Purpose of the Study:

• To evaluate the adequacy of the current static clopidogrel dose in pediatric cardiac patients using P2Y12 reaction unit (PRU) values.
• To determine if a gradual dosage escalation is more appropriate for optimal thromboprophylaxis.
• To propose a hypothetical age-based clopidogrel dosing scheme for this population.

Main Methods:

• Retrospective cohort study of 44 pediatric cardiac patients (0-24 months) receiving clopidogrel for thromboprophylaxis (2018-2021).
• Analysis of patient demographics, diagnoses, clopidogrel dosing, PRU values, and adverse events.
• Application of regression analyses to model clopidogrel dosage as a function of time based on therapeutic PRU values.

Main Results:

• Observed clopidogrel doses achieving therapeutic PRU values were inconsistent with the static low dose recommended by the PICOLO trial.
• Regression analyses did not show a statistically significant difference between predicted and referent dosing, but indicated a trend towards a dosing gradient.
• The findings suggest that a static low dose may not be optimal for achieving consistent therapeutic effects in this age group.

Conclusions:

• Pediatric cardiac patients may benefit from a gradual, age-based escalation of clopidogrel dosage.
• The static low-dose regimen recommended by the PICOLO trial might not be optimal for all patients under 24 months.
• Further prospective studies are warranted to validate age-based clopidogrel dosing strategies in pediatric cardiac patients.